A Study of Tamiflu (Oseltamivir) Treatment in Laboratory-Confirmed Influenza.
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00436124|
Recruitment Status : Terminated (poor recruitment, no patients were enrolled)
First Posted : February 16, 2007
Last Update Posted : February 17, 2017
|Condition or disease||Intervention/treatment||Phase|
|Influenza||Drug: oseltamivir [Tamiflu]||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Randomized, Open Label Study to Evaluate the Effect of Tamiflu on Viral Shedding and on Serum and Cytoplasmic Inflammatory Cytokine Concentrations in Patients With Laboratory-confirmed Influenza|
|Actual Study Start Date :||January 2007|
|Actual Primary Completion Date :||April 2007|
|Actual Study Completion Date :||April 2007|
- Viral shedding; serum and intracellular concentrations of inflammatory cytokines (INFgamma, TNFalpha, IL-6, IL-12).
- Efficacy: Duration of illness, health and functional status, extent and severity of symptoms, incidence of resistant viruses. Safety: AEs.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00436124
|Study Director:||Clinical Trials||Hoffmann-La Roche|